| Morella Corporation Limited (1MC) ORDINARY FULLY PAID |
Materials |
$6 |
Application for quotation of securities - 1MC
|
29 Aug 2024 8:09AM |
$0.036 |
$0.015 |
fallen by
58.33%
|
|
| Ai-Media Technologies Limited (AIM) ORDINARY FULLY PAID |
Industrials |
$127 |
2024 Annual Report (including Appendix 4E)
|
29 Aug 2024 8:09AM |
$0.455 |
$0.610 |
risen by
34.07%
|
|
AIM - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue increased by 7.2% to $66.2 million.
- EBITDA grew by 24.2% to $4.1 million.
- Technology revenue rose 37% to $32.9 million, making up 50% of total revenue.
- Launch of LEXI 3.0 significantly boosted technology sales.
- Net loss after tax reduced to $1.34 million from $4.02 million the previous year.
- No dividends were paid, recommended, or declared during the financial period.
- Investment in R&D continues with further product releases planned.
- A strategic reduction in operational expenditure and headcount was noted.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| McPherson's Limited (MCP) ORDINARY FULLY PAID |
Consumer Staple |
$46 |
FY24 Appendix 4E
|
29 Aug 2024 8:09AM |
$0.458 |
$0.320 |
fallen by
30.05%
|
|
MCP - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue from continuing operations increased by 4.3% to $228.1 million.
- Net profit after tax increased by 11.8% to $9.8 million.
- Earnings per share rose by 8.1% to 7.2 cents per share.
- Dividends declared for FY24 are 6.0 cents per share, fully franked.
- Strong growth in the Health, Wellness & Beauty segment with revenue up 12.5%.
- Improvements in operational efficiency resulted in a 2.7% reduction in cost of goods sold.
- International sales contributed 15% to overall revenue, led by strong performance in New Zealand and Asia.
- Sustainability initiatives led to a 10% reduction in carbon footprint compared to FY23.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Pepper Money Limited (PPM) ORDINARY FULLY PAID |
Financials |
$841 |
Half Yearly Report and Accounts
|
29 Aug 2024 8:09AM |
$1.355 |
$1.895 |
risen by
39.85%
|
|
PPM - Price-sensitive ASX Announcement
Full Release
Key Points
- Pepper Money completed the acquisition of the residual 35% shareholding in Stratton Finance Pty Ltd on 28 March 2024.
- Pepper Money operates in three core segments: Mortgages, Asset Finance, and Loan & Other Servicing.
- For the first half of 2024, Pepper Money's total originations were $3.3 billion, with $1.82 billion in Mortgages and $1.44 billion in Asset Finance.
- The Group had loans and advances of $17.1 billion as at 30 June 2024, reflecting a 7% net portfolio change.
- Net interest income for the half-year ended 30 June 2024 was $170.9 million, down 8% compared to the prior comparable period.
- Total operating income for the half-year ended 30 June 2024 was $186.0 million, down 4% compared to 2023.
- Net profit after income tax for the half-year ended 30 June 2024 was $46.1 million, down 11% compared to 2023.
- A fully franked interim dividend of 5.0 cents per ordinary share was declared, with a payout ratio of 47.50% of Pro-forma NPAT.
- The company maintains a diversified funding platform using public term securitizations, whole loan sales, warehouse facilities, and private term securitizations.
- Pepper Money's net tangible assets per ordinary share as of 30 June 2024 were $1.60.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Dusk Group Limited (DSK) ORDINARY FULLY PAID |
Consumer Discretionary |
$59 |
Dividend/Distribution - DSK
|
29 Aug 2024 8:09AM |
$0.905 |
$0.950 |
risen by
4.97%
|
|
DSK - Price-sensitive ASX Announcement
Full Release
Key Points
- Entity name: Dusk Group Limited
- Security on which the Distribution will be paid: DSK - Ordinary Fully Paid
- Announcement Type: New announcement
- Announcement Date: 29/8/2024
- Distribution Amount: AUD 0.04000000
- Ex Date: 11/9/2024
- Record Date: 12/9/2024
- Payment Date: 26/9/2024
- Type of dividend/distribution: Relates to a period of six months
- Financial reporting or payment period ending: 30/6/2024
- Currency: AUD - Australian Dollar
- Total dividend/distribution payment amount per security: AUD 0.04000000
- Ordinary dividend/distribution franked percentage: 100.0000%
- Applicable corporate tax rate for franking credit: 30.0000%
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Anatara Lifesciences Ltd (ANR) ORDINARY FULLY PAID |
Health Care |
$1 |
$626,000 received in R&D Tax Incentive for FY24
|
29 Aug 2024 8:08AM |
$0.045 |
$0.007 |
fallen by
84.44%
|
|
ANR - Price-sensitive ASX Announcement
Full Release
Key Points
- Anatara Lifesciences receives $626,000 in R&D tax incentive for FY24
- The tax incentive adds to the company's cash position with no debt or loan facilities
- Funds will be used towards Phase 2 IBS clinical trial of GaRP
- Federal R&D tax incentive provides 43.5% rebate for qualifying activities
- GaRP is a multi-component medicine for gastrointestinal conditions like IBS and IBD
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| WEB Travel Group Limited (WEB) ORDINARY FULLY PAID |
Consumer Discretionary |
$1,592 |
AGM Managing Director's Presentation
|
29 Aug 2024 8:08AM |
$8.260 |
$4.405 |
fallen by
46.67%
|
|
WEB - Price-sensitive ASX Announcement
Full Release
Key Points
- Record financial metrics for FY24
- $5.6 billion TTV, $471.5 million revenue, $188.1 million EBITDA
- Goal to achieve $10 billion TTV by FY30
- Significant growth in WebBeds and Webjet OTA
- Increases in international market share and customer satisfaction
- Challenges in inbound tourism and supply chain
- FY25 trading update with continued growth
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Shine Justice Ltd (SHJ) ORDINARY FULLY PAID |
Consumer Discretionary |
$109 |
Appendix 4G
|
29 Aug 2024 8:08AM |
$0.710 |
$0.640 |
fallen by
9.86%
|
|
| WEB Travel Group Limited (WEB) ORDINARY FULLY PAID |
Consumer Discretionary |
$1,592 |
AGM Chair's Address
|
29 Aug 2024 8:08AM |
$8.260 |
$4.405 |
fallen by
46.67%
|
|
| Shine Justice Ltd (SHJ) ORDINARY FULLY PAID |
Consumer Discretionary |
$109 |
FY24 Results Presentation
|
29 Aug 2024 8:08AM |
$0.710 |
$0.640 |
fallen by
9.86%
|
|
SHJ - Price-sensitive ASX Announcement
Full Release
Key Points
- Shine Justice Ltd (SHJ) announced FY24 financial results.
- FY24 revenue was $198.6 million, down 12% from the previous year.
- Net Profit After Tax (NPAT) increased by 82% to $6.0 million.
- Adjusted NPAT was $14.5 million, down 44%.
- EBITDA grew by 17% to $33.8 million, while adjusted EBITDA decreased by 27% to $45.0 million.
- Cash at bank increased by 39% to $29.4 million.
- Net interest-bearing debt rose by 51% to $26.1 million.
- The total dividend for FY24 was 5.5 cents per share, a 267% increase.
- Significant initiatives included divesting non-core businesses and focusing on Class Actions and Personal Injury segments.
- Class Actions portfolio is 74% litigation funded, 17% Shine funded, and 9% Group Costs Order funded.
- Class Actions segment includes strategic expansion in Australia, New Zealand, and potential growth in the USA.
- FY25 outlook includes growth in both Personal Injury and Class Actions, with a continued focus on expense management and cash generation.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Shine Justice Ltd (SHJ) ORDINARY FULLY PAID |
Consumer Discretionary |
$109 |
FY24 Results Overview
|
29 Aug 2024 8:08AM |
$0.710 |
$0.640 |
fallen by
9.86%
|
|
SHJ - Price-sensitive ASX Announcement
Full Release
Key Points
- Total revenue for FY24 is $198.59 million, a decrease of 12.2% from FY23
- EBITDA for FY24 is $33.83 million, a 16.7% increase from FY23
- Adjusted EBITDA for FY24 is $45 million, a 26.7% decrease from FY23
- Net Profit Before Tax (NPBT) for FY24 is $9.65 million, a 59.2% increase from FY23
- Adjusted NPBT for FY24 is $20.82 million, a 45.8% decrease from FY23
- Net Profit After Tax (NPAT) for FY24 is $6.04 million, an 82.4% increase from FY23
- Adjusted NPAT for FY24 is $14.45 million, a 44.4% decrease from FY23
- Gross Operating Cash Flow (GOCF) for FY24 is $51.80 million, a significant turnaround from -$3.91 million in FY23
- Final Dividend per share for FY24 is 4.00 cents, compared to 0.00 cents in FY23
- Total Dividend per share for FY24 is 5.50 cents, a 266.7% increase from FY23
- Earnings per share (EPS) for FY24 is 3.51 cents, an 82.8% increase from FY23
- Adjusted EPS for FY24 is 8.34 cents, a 44.4% decrease from FY23
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Shine Justice Ltd (SHJ) ORDINARY FULLY PAID |
Consumer Discretionary |
$109 |
Dividend/Distribution - SHJ
|
29 Aug 2024 8:08AM |
$0.710 |
$0.640 |
fallen by
9.86%
|
|
| Shine Justice Ltd (SHJ) ORDINARY FULLY PAID |
Consumer Discretionary |
$109 |
2024 Annual Report
|
29 Aug 2024 8:07AM |
$0.710 |
$0.640 |
fallen by
9.86%
|
|
| Shine Justice Ltd (SHJ) ORDINARY FULLY PAID |
Consumer Discretionary |
$109 |
Appendix 4E - Preliminary financial statements FY24
|
29 Aug 2024 8:07AM |
$0.710 |
$0.640 |
fallen by
9.86%
|
|
SHJ - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue from ordinary activities decreased by 12.22% to $198,589,000.
- Profit from ordinary activities after tax increased by 82.11% to $6,037,000.
- Net comprehensive income increased by 71.73% to $5,049,000.
- Interim dividend of 1.50 cents per share paid on 22 March 2024.
- Final dividend of 4.00 cents per share determined.
- Ex-dividend date is 26 September 2024, and the payment date is 14 October 2024.
- The company does not operate a dividend reinvestment plan.
- Net tangible asset per security increased to $1.36 from $1.34.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Noxopharm Limited (NOX) ORDINARY FULLY PAID |
Health Care |
$34 |
Appendix 4E Preliminary Final Report
|
29 Aug 2024 8:07AM |
$0.105 |
$0.115 |
risen by
9.52%
|
|
NOX - Price-sensitive ASX Announcement
Full Release
Key Points
- Signed several Material Transfer Agreements (MTAs) to evaluate Noxopharm’s Sofra platform.
- Scaled up production of SOF-SKN lupus medication for regulatory submissions.
- New data showed SOF-VAC mRNA vaccine enhancer significantly reduces inflammation driven by mRNA.
- Secured Orphan Drug Designation (ODD) status for CRO-67 for pancreatic cancer treatment.
- Encouraging preclinical data for CRO-67 dual-cell therapy drug in treating pancreatic cancer.
- Received $100,000 from Tour de Cure for brain cancer drug research.
- Reduced expenditure through streamlining operations and restructuring.
- Renewed strategic partnership with Hudson Institute of Medical Research.
- Utilized short term borrowings repaid with research and development rebate.
- Net loss decreased significantly from $15M in 2023 to $3.6M in 2024.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Austco Healthcare Limited (AHC) ORDINARY FULLY PAID |
Health Care |
$135 |
Appendix 4G and Corporate Governance Statement
|
29 Aug 2024 8:07AM |
$0.220 |
$0.370 |
risen by
68.18%
|
|
| Austco Healthcare Limited (AHC) ORDINARY FULLY PAID |
Health Care |
$135 |
Austco FY24 Results Media Release
|
29 Aug 2024 8:07AM |
$0.220 |
$0.370 |
risen by
68.18%
|
|
AHC - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue from customers up 39% to a record high $58.2 million
- EBITDA grew by 126% to $8.1 million
- Net Profit After Tax (NPAT) increased by 213% to $7.1 million
- Unfilled Contracted Orders grew to $50.3 Million
- Organic growth and acquisitions contributed to revenue growth
- Gross Margin for FY24 was $30.7 million
- Overhead expenses increased by $4.3 million to $25.0 million
- No dividend declared to fund growth and acquisitions
- Significant investments in R&D and new product releases
- Strong cash position and increased working capital efficiency
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Austco Healthcare Limited (AHC) ORDINARY FULLY PAID |
Health Care |
$135 |
Appendix 4E & FY24 Financial Statements
|
29 Aug 2024 8:07AM |
$0.220 |
$0.370 |
risen by
68.18%
|
|
AHC - Price-sensitive ASX Announcement
Full Release
Key Points
- Austco Healthcare Limited reported a 39% increase in revenue from customers to $58.2 million for FY24.
- Revenue growth was driven by organic growth of $7.0 million and acquisitions amounting to $9.2 million.
- EBITDA was $8.1 million, marking a 126% increase compared to FY23.
- Net Profit After Tax (NPAT) reached $7.1 million, a 213% increase from the previous year.
- Gross Margin increased by 37% to $30.7 million, although the margin percentage slightly declined to 52.7%.
- Overhead expenses rose by $4.3 million to $25.0 million, partly due to acquisitions and M&A costs.
- The company did not declare a dividend for the year ended 30 June 2024.
- The acquisitions of Teknocorp and Amentco were significant, contributing $6.5 million and $2.7 million in revenues respectively.
- Austco Healthcare invested $4.5 million in R&D, focusing on its nurse call and clinical communications platform, Tacera.
- The order backlog at the end of the period was $50.3 million, indicating strong future revenue potential.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$141 |
2024 Annual General Meeting
|
29 Aug 2024 8:06AM |
$1.150 |
$0.925 |
fallen by
19.57%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$141 |
FY24 Appendix 4G and Corporate Governance Statement
|
29 Aug 2024 8:06AM |
$1.150 |
$0.925 |
fallen by
19.57%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$141 |
FY24 Financial Results Presentation
|
29 Aug 2024 8:06AM |
$1.150 |
$0.925 |
fallen by
19.57%
|
|
TRJ - Price-sensitive ASX Announcement
Full Release
Key Points
- Extraordinary industry-wide issues impacted TRJ’s FY24 result, particularly during H1 with destocking in the Components & Consumables Segment, and in H2 with a slowdown in pharmaceutical sector capital equipment orders.
- Net revenue was slightly down with $155.0M in FY24 compared to $162.2M in FY23.
- nEBITDA Core decreased from $23.9M in FY23 to $17.2M in FY24.
- Commercialization of products within the Disruptive Technologies segment is progressing, with the Microsampling portfolio to be nEBITDA breakeven in FY25.
- Net profit after tax plus amortization (NPATA) was $0.6M in FY24, down from $5.8M in FY23.
- Proforma Gross Margin decreased slightly from 43.2% in FY23 to 41.1% in FY24 due to under-utilization of manufacturing infrastructure.
- Revenue and nEBITDA in H2 showed improvement over H1, returning to growth.
- Financial guidance for the upcoming year includes expected net revenue of $160.0M-$165.0M and nEBITDA of $17.0M-$19.0M.
- The company anticipates Components & Consumables to continue at historical growth rates post-destocking, and Capital Equipment demand within the pharmaceutical sector to return to typical order demand in CY25.
- Trajan Group Holdings Limited emphasizes a robust business model, high barriers to market entry, and long-term shareholder value focus.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$141 |
FY24 Financial Results Release
|
29 Aug 2024 8:06AM |
$1.150 |
$0.925 |
fallen by
19.57%
|
|
TRJ - Price-sensitive ASX Announcement
Full Release
Key Points
- Rebounded performance in the second half with Core nEBITDA up 48.7% on H1
- Full Year Net Revenue $155.0M, within 5% of the previous year
- Core nEBITDA at $17.2M, exceeding guidance
- Destocking activities by key customers in H1 placed strain on business
- Improved revenue in Components & Consumables and Disruptive Technologies in H2
- Capital Equipment segment experienced softer demand, expected to persist in H1 FY25
- Net Debt reduction of $4.7M to $32.9M
- Proforma Gross Margin for FY24 at 41.1%
- Guidance for FY25 Net Revenue is $160.0M to $165.0M, and Group nEBITDA $17.0M to $19.0M
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$141 |
FY24 Appendix 4E and Annual Report
|
29 Aug 2024 8:06AM |
$1.150 |
$0.925 |
fallen by
19.57%
|
|
TRJ - Price-sensitive ASX Announcement
Full Release
Key Points
- Trajan Group Holdings Limited reported a net revenue of $155.0 million for FY24.
- The company achieved a normalised EBITDA of $17.2 million.
- Proforma gross margin stood at 41.1%.
- Revenue for the Components & Consumables segment increased by approximately 25% in the third and fourth quarters compared to the first quarter.
- Significant progress was made in new technologies, including over 40% growth in Emitter Tips for Mass Spectrometry and a 140% increase in microbiopsy devices supplied for investigational use.
- Trajan's ESG program includes partnering with Carbonhound to establish a carbon emissions baseline and developing a 2024 ESG Strategy.
- The Capital Equipment segment reported a net revenue of $53.9 million and a normalised EBITDA of $9.7 million.
- Trajan launched its first environmental workflow solution, the CHRONECT Workstation, in August 2024.
- The company's efforts toward sustainability include redesigning sustainable packaging solutions and focusing on reducing emissions.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Morella Corporation Limited (1MC) ORDINARY FULLY PAID |
Materials |
$6 |
Results of Non-Renounceable Rights Issue
|
29 Aug 2024 8:05AM |
$0.036 |
$0.015 |
fallen by
58.33%
|
|
1MC - Price-sensitive ASX Announcement
Full Release
Key Points
- Morella Corporation Limited (ASX:1MC) announced the results of its non-renounceable rights issue on 29 August 2024.
- The rights issue, which closed on 22 August 2024, received applications for 23,621,178 new shares, raising a total of $850,363.
- The company's Board committed to over $275,000 of the raised amount.
- 11,810,589 free-attaching new options will be issued, convertible into shares expiring on 31 August 2026 at $0.072 per option.
- An Appendix 2A and Appendix 3G will be filed with ASX in compliance with the Corporations Act 2001 (Cth) and ASX Listing Rules.
- The shortfall offer will remain open for up to 3 months from the closing date with the same price and terms as the rights issue.
- Funds raised will support joint venture projects in Western Australia and Nevada USA.
- Morella Corporation is focused on lithium and battery minerals exploration and development.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Catalyst Metals Limited (CYL) ORDINARY FULLY PAID |
Materials |
$1,730 |
Maiden profit for Catalyst
|
29 Aug 2024 8:05AM |
$2.100 |
$6.870 |
risen by
227.14%
|
|
CYL - Price-sensitive ASX Announcement
Full Release
Key Points
- Catalyst Metals reported its first full year financial results for FY2024.
- The company produced 110,000 ounces of gold from two operations.
- Revenue for FY2024 was A$317 million.
- EBITDA for FY2024 was A$63 million.
- Net profit after tax, excluding impairments, was A$37 million.
- Liquidity at 30 June 2024 was A$46 million.
- Catalyst plans to expand operations along the Plutonic Gold Belt.
- The company aims to increase its production profile towards 200,000 ounces annually.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Goals & planningInvesting goal hubsSaving to build wealth
Saving for happy retirement 
Call 1300 880 160
Start a chat
Schedule a call
